Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal …
L Käsmann, C Eze, J Taugner, O Roengvoraphoj… - Radiation …, 2020 - Springer
Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer
treatment. Preclinical studies investigating combination of ICI with radiation show a …
treatment. Preclinical studies investigating combination of ICI with radiation show a …
[HTML][HTML] Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)
M Łazar-Poniatowska, A Bandura… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Concurrent chemoradiotherapy (CHRT) remains the therapeutic standard for locally
advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) …
advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) …
A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and …
S Hindocha, TG Charlton, K Linton-Reid, B Hunter… - …, 2022 - thelancet.com
Background Surveillance is universally recommended for non-small cell lung cancer
(NSCLC) patients treated with curative-intent radiotherapy. High-quality evidence to inform …
(NSCLC) patients treated with curative-intent radiotherapy. High-quality evidence to inform …
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with …
K Gennen, L Käsmann, J Taugner, C Eze, M Karin… - Radiation …, 2020 - Springer
Background/aim mmune checkpoint inhibition (CPI) has an increasing impact in the
multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC) …
multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC) …
Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival …
J Taugner, L Käsmann, C Eze, A Tufman, N Reinmuth… - Cancers, 2021 - mdpi.com
Simple Summary Concurrent platinbased chemoradiotherapy followed by maintenance
treatment with the PD-L1 inhibitor durvalumab is the new standard of care for inoperable …
treatment with the PD-L1 inhibitor durvalumab is the new standard of care for inoperable …
Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 …
C Ostheimer, M Mäurer, N Ebert, D Schmitt… - Strahlentherapie und …, 2021 - Springer
Background In radical radiochemotherapy (RCT) of inoperable non-small-cell lung cancer
(NSCLC) typical prognostic factors include T-and N-stage, while there are still conflicting …
(NSCLC) typical prognostic factors include T-and N-stage, while there are still conflicting …
Use of durvalumab in stage III n on‐small‐cell lung cancer based on eligibility for the PACIFIC study
E Boys, B Gao, R Hui, I da Silva, E Hau, H Gee… - Thoracic …, 2023 - Wiley Online Library
Background Durvalumab following concurrent chemoradiotherapy is standard treatment for
unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial …
unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial …
Impact of underlying pulmonary diseases on treatment outcomes in early-stage non-small cell lung cancer treated with definitive radiotherapy
H Kim, H Yoo, H Pyo, YC Ahn, JM Noh… - … journal of chronic …, 2019 - Taylor & Francis
Purpose Current guidelines recommend definitive radiotherapy for patients with medically
inoperable early-stage non-small cell lung cancer (NSCLC). However, the impact of …
inoperable early-stage non-small cell lung cancer (NSCLC). However, the impact of …
[HTML][HTML] Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with …
L Käsmann, J Taugner, C Eze, A Nieto… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background Concurrent platinum-based chemoradiotherapy (CRT) followed by durvalumab
maintenance treatment represents the new standard of care in unresectable stage III non …
maintenance treatment represents the new standard of care in unresectable stage III non …
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy±immune checkpoint inhibition
M Unterrainer, J Taugner, L Käsmann… - European journal of …, 2021 - Springer
Background The PET-derived metabolic tumor volume (MTV) is an independent
prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the prognostic …
prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the prognostic …